Ann: Completion of Viral Vector Manufacturing for Phase 1 trial, page-7

ALA's MC is about 26m, about 3.5m cash and working with IMU to get the iNKT pre-clinical trial underway.

CHM's MC is about 28m, about 8m cash at hand, got 2 phase 1 trials running and is about to start a third one.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of
patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in
recurrent / progressive glioblastoma. Initial positive data has been presented on patients
treated in the first two dose levels of the trial. Additional work is being undertaken to expand
CLTX to additional solid tumours, beginning with metastatic melanoma.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the worldrenowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM
2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in
preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours.

CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell
platform. Data from the complete phase 1 clinical trial was published in March 2022,
demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising
activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM
0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform,
Chimeric has initiated development of four new next generation NK and CAR NK assets with
plans for phase 1 clinical trials in solid tumours and blood cancers.

That's why I continue to say, CHM totally undervalued.